NaPro sells 2M shares Mar 27, 2004
Boulder-based biotech company NaPro BioTherapeutics Inc. has sold 2 million shares of its common stock to two unidentified institutional investors. NaPro (Nasdaq: NPRO) sold the shares at $2. (Denver Business Journal, CO)
FRI Mar 26, 04, 8:01 AM Mar 26, 2004
NaPro Announces the Sale of Two Million Common Shares. NaPro Announces the Sale of Two Million Common Shares. (PR Newswire)
Mylan will appeal judge's ruling that its cancer drug violates ... Dec 26, 2003
U.S. District Judge Arthur Schwab -- who had rejected Mylan's request that he recuse himself because he and the company had a prior business relationship that turned sour -- ruled earlier this week that Mylan infringed on patents held by NaPro Biotherapeutics Inc. of Boulder, Colo. Allegations that NaPro had intentionally misled the U.S. Patent and Trademark Office during interviews with examiners in 1997 were "unjustified," Schwab said after the nonjury trial (Pittsburgh Tribune-Review, PA)
Court Rules in Favor of NaPro i . . . Dec 24, 2003
The Court's ruling, affirming the validity of these patents, speaks to the integrity of our company and the conduct and professionalism of our people," stated Leonard P. Shaykin, Chairman and Chief Executive Officer. On December 12, 2003, NaPro announced the closing of the sale of its worldwide generic injectable paclitaxel business to Mayne Pharma for $71.7 million in cash. The patents which are the subject of this litigation were sold to Mayne Pharma as part of the injectable paclitaxel...... (Pressemitteilung)
Court rules in favor of NaPro in patent case Dec 24, 2003
Boulder-based NaPro BioTherapeutics Inc. (Nasdaq: NPRO) announced today it received a favorable court ruling in its case against Mylan Laboratories Inc. regarding certain paclitaxel formulation patents. On Dec. 12, NaPro had announced it closed the sale of its generic injectable paclitaxel business to Mayne Pharma for $71 (Denver Business Journal, CO)
NaPro completes $71.7M sale of worldwide paclitaxel business Dec 13, 2003
Boulder-based NaPro BioTherapeutics Inc. (Nasdaq: NPRO), a life science company focused on the development of treatments for cancer and hereditary disease, has sold its worldwide generic injectable paclitaxel business to Mayne Pharma for $71. NaPro first announced the proposed sale on Aug. 26 (Bizjournals.com)
NaPro numbers down Nov 13, 2003
Boulder-based NaPro BioTherapeutics Inc. (Nasdaq: NPRO) reported a 2003 third quarter net loss of $6. Out of the sale, NaPro will retire approximately $22 million in debt and payables arising from its development relationship with Abbott Laboratories (Denver Business Journal, CO)
Reminder - NaPro BioTherapeutics to Present at The Wall Street ... Nov 10, 2003
Reminder - NaPro BioTherapeutics to Present at The Wall Street Analyst Forum On November 10. Nov. 10 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) will present at The Wall Street Analyst Forum analyst conference to be held in New York City November 10 - 11, 2003 (PRNewswire (press release)
Stocks close higher Oct 7, 2003
And Mayne Group jumped four cents to $3.38 after a United States court ruled infavour of Mayne partner NaPro Biotherapeutics Inc in a patent infringement ... (NEWS.com.au, Australia)
